Skip to main content


Some very disappointing news released today, as seen on Reuters: Oct 18 (Reuters) - Abbott Laboratories Inc said its partner Reata Pharmaceuticals was discontinuing a late-stage trial of their potential blockbuster treatment for chronic kidney dis...
  1.   Thursday, 18 October 2012
  2.   General nephrology
  3. 0 Comments
While the nephrology community awaits the outcome of a much awaited study of tolvaptan on progression of polycystic kidney disease (PCKD), a new story is emerging with very intriguing possibilities.   Previously on UKidney, we reported the disapp...
  1.   Monday, 06 August 2012
  2.   General nephrology
  3. 0 Comments
Top-line results for the EVOLVE study using cinacalcet (Sensipar) in patients with end-stage renal disease (ESRD) were reported last week. In this phase 3 placebo-controlled randomized trial of 3,883 patients with secondary hyperparathyroidism, ...
  1.   Wednesday, 20 June 2012
  2.   General nephrology
  3. 3 Comments
At the end of 2011, Novartis suspended the ALTITUDE Study, effectively ending the possibility that the direct renin inhibitor (DRI) Aliskiren will play a significant role in the management of patients with CKD already on an ACE or ARB. This developme...
  1.   Monday, 16 January 2012
  2.   General nephrology
  3. 8 Comments
In a stunning development, Novartis said Tuesday that it will terminate the late-stage ALTITUDE study investigating Rasilez (aliskiren) in patients with type 2 diabetes and renal impairment on the recommendation of an independent data monitoring c...
  1.   Tuesday, 20 December 2011
  2.   Hypertension
  3. 10 Comments
Jordan Weinstein doesn't have any blog post yet.
Unable to load tooltip content.